Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the approval of safe and effective anticancer therapies. With the increasing complexity of cancer-related policy issues, the need for active engagement of cancer researchers and physician-scientists in the policymaking process has never been greater.Read More
Two of the nation’s preeminent leaders in cancer research and policy took the stage Sunday morning at the Opening Ceremony of the American Association for Cancer Research Annual Meeting 2019.
Norman “Ned” Sharpless, MD, FAACR, and Douglas R. Lowy, MD, discussed recent progress against cancer from the vantage point of the National Cancer Institute (NCI). Sharpless has served as director of the NCI since October 2017, and will soon leave the agency to become acting commissioner of the U.S. Food and Drug Administration (FDA). Lowy will take over as NCI acting director, a position he held from 2015-2017.
Sharpless and Lowy discussed the rapid pace of progress in cancer care, drug development, clinical trials, and research funding over the past few years, and vowed to continue the momentum in their new roles in Washington, D.C.Read More
This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at supporting pediatric cancer research. The legislation calls for expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.Read More
The Affordable Care Act, which was enacted in 2010 and recently survived an effort to dismantle it, was the focus of a panel held Tuesday at the American Association for Cancer Research Annual Meeting 2017.Read More